These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
567 related articles for article (PubMed ID: 21213308)
1. Nonnative aggregation of an IgG1 antibody in acidic conditions: part 1. Unfolding, colloidal interactions, and formation of high-molecular-weight aggregates. Brummitt RK; Nesta DP; Chang L; Chase SF; Laue TM; Roberts CJ J Pharm Sci; 2011 Jun; 100(6):2087-103. PubMed ID: 21213308 [TBL] [Abstract][Full Text] [Related]
2. Nonnative aggregation of an IgG1 antibody in acidic conditions, part 2: nucleation and growth kinetics with competing growth mechanisms. Brummitt RK; Nesta DP; Chang L; Kroetsch AM; Roberts CJ J Pharm Sci; 2011 Jun; 100(6):2104-19. PubMed ID: 21213307 [TBL] [Abstract][Full Text] [Related]
3. Comparative effects of pH and ionic strength on protein-protein interactions, unfolding, and aggregation for IgG1 antibodies. Sahin E; Grillo AO; Perkins MD; Roberts CJ J Pharm Sci; 2010 Dec; 99(12):4830-48. PubMed ID: 20821389 [TBL] [Abstract][Full Text] [Related]
4. Conformational and Colloidal Stabilities of Isolated Constant Domains of Human Immunoglobulin G and Their Impact on Antibody Aggregation under Acidic Conditions. Yageta S; Lauer TM; Trout BL; Honda S Mol Pharm; 2015 May; 12(5):1443-55. PubMed ID: 25871775 [TBL] [Abstract][Full Text] [Related]
5. Aggregation of anti-streptavidin immunoglobulin gamma-1 involves Fab unfolding and competing growth pathways mediated by pH and salt concentration. Kim N; Remmele RL; Liu D; Razinkov VI; Fernandez EJ; Roberts CJ Biophys Chem; 2013 Feb; 172():26-36. PubMed ID: 23334430 [TBL] [Abstract][Full Text] [Related]
6. Aggregation and pH-temperature phase behavior for aggregates of an IgG2 antibody. Sahin E; Weiss WF; Kroetsch AM; King KR; Kessler RK; Das TK; Roberts CJ J Pharm Sci; 2012 May; 101(5):1678-87. PubMed ID: 22246657 [TBL] [Abstract][Full Text] [Related]
7. Examination of thermal unfolding and aggregation profiles of a series of developable therapeutic monoclonal antibodies. Brader ML; Estey T; Bai S; Alston RW; Lucas KK; Lantz S; Landsman P; Maloney KM Mol Pharm; 2015 Apr; 12(4):1005-17. PubMed ID: 25687223 [TBL] [Abstract][Full Text] [Related]
8. Partial unfolding of a monoclonal antibody: role of a single domain in driving protein aggregation. Mehta SB; Bee JS; Randolph TW; Carpenter JF Biochemistry; 2014 May; 53(20):3367-77. PubMed ID: 24804773 [TBL] [Abstract][Full Text] [Related]
9. Formulation design and high-throughput excipient selection based on structural integrity and conformational stability of dilute and highly concentrated IgG1 monoclonal antibody solutions. Bhambhani A; Kissmann JM; Joshi SB; Volkin DB; Kashi RS; Middaugh CR J Pharm Sci; 2012 Mar; 101(3):1120-35. PubMed ID: 22147527 [TBL] [Abstract][Full Text] [Related]
10. A thermal-cycling method for disaggregating monoclonal antibody oligomers. Sadavarte RH; Ghosh R J Pharm Sci; 2014 Mar; 103(3):870-8. PubMed ID: 24549731 [TBL] [Abstract][Full Text] [Related]
11. Perturbation of thermal unfolding and aggregation of human IgG1 Fc fragment by Hofmeister anions. Zhang-van Enk J; Mason BD; Yu L; Zhang L; Hamouda W; Huang G; Liu D; Remmele RL; Zhang J Mol Pharm; 2013 Feb; 10(2):619-30. PubMed ID: 23256580 [TBL] [Abstract][Full Text] [Related]
12. Unfolding and aggregation of a glycosylated monoclonal antibody on a cation exchange column. Part II. Protein structure effects by hydrogen deuterium exchange mass spectrometry. Guo J; Carta G J Chromatogr A; 2014 Aug; 1356():129-37. PubMed ID: 25011681 [TBL] [Abstract][Full Text] [Related]
13. High throughput formulation screening for global aggregation behaviors of three monoclonal antibodies. Li Y; Mach H; Blue JT J Pharm Sci; 2011 Jun; 100(6):2120-35. PubMed ID: 21491438 [TBL] [Abstract][Full Text] [Related]
14. Temperature-ramped studies on the aggregation, unfolding, and interaction of a therapeutic monoclonal antibody. Menzen T; Friess W J Pharm Sci; 2014 Feb; 103(2):445-55. PubMed ID: 24382634 [TBL] [Abstract][Full Text] [Related]
15. Stability of monoclonal antibodies at high-concentration: head-to-head comparison of the IgG1 and IgG4 subclass. Neergaard MS; Nielsen AD; Parshad H; Van De Weert M J Pharm Sci; 2014 Jan; 103(1):115-27. PubMed ID: 24282022 [TBL] [Abstract][Full Text] [Related]
16. Factors to Govern Soluble and Insoluble Aggregate-formation in Monoclonal Antibodies. Fukuda J; Iwura T; Yanagihara S; Kano K Anal Sci; 2015; 31(12):1233-40. PubMed ID: 26656811 [TBL] [Abstract][Full Text] [Related]
17. Contribution of variable domains to the stability of humanized IgG1 monoclonal antibodies. Ionescu RM; Vlasak J; Price C; Kirchmeier M J Pharm Sci; 2008 Apr; 97(4):1414-26. PubMed ID: 17721938 [TBL] [Abstract][Full Text] [Related]
18. Unfolding and aggregation of a glycosylated monoclonal antibody on a cation exchange column. Part I. Chromatographic elution and batch adsorption behavior. Guo J; Zhang S; Carta G J Chromatogr A; 2014 Aug; 1356():117-28. PubMed ID: 25015241 [TBL] [Abstract][Full Text] [Related]
19. Correlations between changes in conformational dynamics and physical stability in a mutant IgG1 mAb engineered for extended serum half-life. Majumdar R; Esfandiary R; Bishop SM; Samra HS; Middaugh CR; Volkin DB; Weis DD MAbs; 2015; 7(1):84-95. PubMed ID: 25524268 [TBL] [Abstract][Full Text] [Related]
20. Effects of temperature and osmolytes on competing degradation routes for an IgG1 antibody. Roberts CJ; Nesta DP; Kim N J Pharm Sci; 2013 Oct; 102(10):3556-66. PubMed ID: 23873602 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]